Back to Search Start Over

The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF.

Authors :
RAO, VISHAL N.
KALTENBACH, LISA A.
GRANGER, BRADI B.
FONAROW, GREGG C.
AL-KHALIDI, HUSSEIN R.
ALBERT, NANCY M.
BUTLER, JAVED
ALLEN, LARRY A.
LANFEAR, DAVID E.
ARIELY, DAN
MILLER, JULIE M.
BRODSKY, MICHAEL A.
LALONDE, THOMAS A.
LAFFERTY, JAMES C.
GRANGER, CHRISTOPHER B.
HERNANDEZ, ADRIAN F.
DEVORE, ADAM D.
Durham, North Carolina; Los Angeles, California; Cleveland, Ohio; Jackson, Misssissippi, Aurora, Colorado; Detroit, Michigan; Ewa Beach, Hawaii; Staten Island, New York
Source :
Journal of Cardiac Failure; Oct2022, Vol. 28 Issue 10, p1487-1496, 10p
Publication Year :
2022

Abstract

<bold>Background: </bold>It is unknown whether digital applications can improve guideline-directed medical therapy (GDMT) and outcomes in heart failure with reduced ejection fraction (HFrEF).<bold>Methods and Results: </bold>Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure trial (CONNECT-HF) included an optional, prospective ancillary study of a mobile health application among patients hospitalized due to HFrEF. Digital users were matched to nonusers from the usual-care group. Coprimary outcomes included change in opportunity-based composite HF quality scores and HF rehospitalization or all-cause mortality. Among 2431 patients offered digital applications across the United States, 1526 (63%) had limited digital access or insufficient data, 425 (17%) were digital users, and 480 (20%) declined use. Digital users were similar in age to those who declined use (mean 58 vs 60 years; P = 0.031). Digital users (n = 368) vs matched nonusers (n = 368) had improved composite HF quality scores (48.0% vs 43.6%; + 4.76% [3.27-6.24]; P = 0.001) and composite clinical outcomes (33.0% vs 39.6%; HR 0.76 [0.59-0.97]; P = 0.027).<bold>Conclusions: </bold>Among participants in the CONNECT-HF trial, use of digital applications was modest but was associated with higher HF quality-of-care scores, including use of GDMT and better clinical outcomes. Although cause and effect cannot be determined from this study, the application of technology to guide GDMT use and dosing among patients with HFrEF warrants further investigation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10719164
Volume :
28
Issue :
10
Database :
Supplemental Index
Journal :
Journal of Cardiac Failure
Publication Type :
Academic Journal
Accession number :
159415881
Full Text :
https://doi.org/10.1016/j.cardfail.2022.07.050